Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy
Sponsor: AstraZeneca
Terminated
Study was terminated for business reasons; not due to safety or efficacy concerns.
A PHASE2 clinical study on Crohn's Disease, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 14 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Terminated PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Aug 2018 — Jun 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Terminated PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .